Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria

M. Thomas, D. Price, R. Segarra, E. Garcia Gil (Southampton, Aberdeen, United Kingdom; Barcelona, Spain)

Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session: New clinical evidence for asthma and COPD treatments
Session type: Thematic Poster Session
Number: 2412
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Thomas, D. Price, R. Segarra, E. Garcia Gil (Southampton, Aberdeen, United Kingdom; Barcelona, Spain). Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria. Eur Respir J 2014; 44: Suppl. 58, 2412

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014

The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015

QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD
Source: International Congress 2014 – Markers
Year: 2014

Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014